Top Markets
#1 Cortex Cortex +32.82%
#2 龙虾 (Lobster) 龙虾 (Lobster) +32.56%
#3 Akedo Akedo +23.89%
#4 DexNet DexNet +23.19%
#5 Pons Pons +16.16%
#6 wojak wojak +15.73%
#7 OpenEden OpenEden +15.27%
#8 APEX APEX +13.92%
#9 The Black Bull The Black Bull +10.83%
#10 Official Trump Official Trump +9.80%
Coin of the day
Cortex Cortex
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
D&D Pharmatech D&D Pharmatech

D&D Pharmatech

347850
Clasificación en acciones #7194
Established in 2014 and headquartered in Seongnam-si, South Korea, D&D... Established in 2014 and headquartered in Seongnam-si, South Korea, D&D Pharmatech Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing pharmaceutical treatments in both South Korea and the United States. The company's robust drug pipeline includes several candidates currently in clinical development: Phase II Trials: NLY01-PD, NLY01-AD, and NLY01-D are being investigated for their efficacy against Parkinson's disease, Alzheimer's disease, and type 2 diabetes, respectively. Completed Phase IIa Trial: P4M01 has successfully finished its Phase IIa study for the treatment of periodontal disease. Phase I Trials: A significant portion of its portfolio is in early human trials, encompassing DD01 for obesity, diabetes, and nonalcoholic steatohepatitis (NASH); TLY012, targeting NASH-liver fibrosis, chronic pancreatitis, and systemic sclerosis; PMI03, focused on Parkinson's disease, Alzheimer's disease, and neuroinflammation; PMI04, addressing Parkinson's disease, Alzheimer's disease, ALS, and depression; and PMI05 and PMI06, both exploring applications in oncology and immuno-oncology. Beyond the clinical stage, D&D Pharmatech is actively developing a range of preclinical compounds. These include NLY03 for stroke and Parkinson's disease; DD03 for obesity and NASH; TLY014, designed to modulate the tumor microenvironment; PMI31 for various cancer types; and VT01 for Parkinson's disease. Further research involves NLY02 for Parkinson's and Alzheimer's diseases; NLY12 for type 2 diabetes and obesity; DD02 for type 2 diabetes; PMI21 for prostate cancer; and PMI07 for oncology and fibrotic conditions. Additionally, the company strategically applies big data analytics to enhance its central nervous system drug research and diagnostics initiatives.
Precio por acción
$38.45
Capitalización bursátil
$1.68B
Cambio (1 día)
-1.24%
Cambio (1 año)
50.36%
País
KR
Comercio D&D Pharmatech (347850)

Categoría

Healthcare
Historial del precio de la acción de D&D Pharmatech (347850)
Precio más alto de cierre: $40.40 el 2026-08-01

Precio más bajo de cierre: $5.98 el 2024-04-01
Historial del precio de la acción de D&D Pharmatech desde 2024 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2026 (TTM) -17.08%
2025 682.94%
2024 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $548.36 39.87%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.06K 50.29%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.53 -12.48%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $140.81 475.44%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $765.25 7.74%
CH